MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer
- PMID: 37350119
- DOI: 10.1089/thy.2023.0240
MERAIODE: A Phase II Redifferentiation Trial with Trametinib and 131I in Metastatic Radioactive Iodine Refractory RAS Mutated Differentiated Thyroid Cancer
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Medical
